SCHEMBL25245488

SCHEMBL25245488

COC(=O)c1cccc(B2OC(C)(C)C(C)(C)O2)c1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.39
LMNA P02545 1/20 0.39
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 4/20 0.39
GAA P10253 2/20 0.39
HSD17B10 Q99714 3/20 0.38
CFTR P13569 1/20 0.38
ALOX5 P09917 1/20 0.38
HPGD P15428 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
POLB P06746 2/20 0.37
ATM Q13315 1/20 0.37
UCHL1 P09936 1/20 0.37
KMT2A Q03164 2/20 0.36
MAPT P10636 2/20 0.35
LIPE Q05469 2/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA5A P35218 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16454773 0.87 IDO1 (0.35) LMNAALDH1A1KDM4EGAAHSD17B10
SCHEMBL16237751 0.87 UCHL1 (0.48) TSHRLMNAALDH1A1KDM4EHSD17B10
SCHEMBL9986523 0.85 LMNA (0.47) TSHRLMNAALDH1A1KDM4EHSD17B10
SCHEMBL562324 0.84 LMNA (0.40) TSHRLMNAALDH1A1KDM4EHSD17B10
SCHEMBL31710278 0.84 LMNA (0.44) TSHRLMNAALDH1A1KDM4EHSD17B10
SCHEMBL29627829 0.83 SLC6A4 (0.39) TSHRLMNAALDH1A1KDM4EHSD17B10
SCHEMBL19923134 0.83 PDK2 (0.40) TSHRLMNAALDH1A1KDM4EHSD17B10
SCHEMBL1526822 0.83 ALDH1A1 (0.45) TSHRLMNAALDH1A1KDM4EGAA
SCHEMBL17939979 0.83 SLC6A4 (0.39) TSHRLMNAALDH1A1KDM4EHSD17B10
SCHEMBL17442464 0.83 LMNA (0.39) TSHRLMNAALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179000-A1 METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-06-05 US disclosed
EP-4452918-A1 METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2024-10-30 EP disclosed
WO-2023122276-A1 METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2023-06-29 WO disclosed
WO-2023122276-A1 METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179000-A1 METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF GRM3, GRM2, GRM1 TSHR 565/4885LMNA 4761/4885ALDH1A1 4468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.